Source: International Congress 2019 – Innovations in idiopathic pulmonary fibrosis
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
J. Swigris (Denver, United States of America), S. Nathan (Falls Church, United States of America), R. Tighe (Durham, United States of America), S. Nagra (Palo Alto, United States of America), C. Rabe (South San Francisco, United States of America), D. Kelkhoff (South San Francisco, United States of America), T. Switzer (South San Francisco, United States of America), N. Kolatkar (South San Francisco, United States of America), P. Belloni (South San Francisco, United States of America), J. Golden (San Francisco, United States of America). STARMAP: an observational study to assess disease-relevant outcomes using home-monitoring devices in patients with idiopathic pulmonary fibrosis (IPF). 1333

Member's Comments

No comment yet.

Related content which might interest you: PROOF: A prospective observational registry to describe the disease course and outcomes of idiopathic pulmonary fibrosis patients in a real-world clinical setting in Belgium and Luxembourg: Exposure in the interim report of 175 IPF patients Source: International Congress 2016 – IPF clinical Year: 2016 Exploring barriers to Pirfenidone adherence in patients with idiopathic pulmonary fibrosis: a prospective study Source: Virtual Congress 2020 – Natural history and management of interstitial lung diseases of known cause Year: 2020 PROOF-registry: A prospective observational registry to describe the disease course and outcomes of IPF patients in a real-world clinical setting- An interim report Source: International Congress 2015 – IPF: clinical aspects Year: 2015 Does delay in review of newly-diagnosed idiopathic pulmonary fibrosis (IPF) worsen outcomes? Source: International Congress 2018 – News on the diagnosis of idiopathic interstitial pneumonia Year: 2018 Real-life experience with pirfenidone in idiopathic pulmonary fibrosis (IPF) in a single centre in Italy. A retrospective study. Source: International Congress 2017 – IPF: from the bench to the bedside Year: 2017 Perceptions, experiences and information needs of patients with idiopathic pulmonary fibrosis (IPF): A qualitative study Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis Year: 2012 The added value of comorbidities in predicting survival in idiopathic pulmonary fibrosis: a multicentre observational study Source: Eur Respir J, 53 (3) 1801587; 10.1183/13993003.01587-2018 Year: 2019 Healthy survivor bias in patients with idiopathic pulmonary fibrosis in clinical registries. Source: Virtual Congress 2021 – News in treatment and diagnosis of idiopathic interstitial pneumonia Year: 2021 Long-term safety of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF): Pooled analysis of 4 clinical trials Source: International Congress 2016 – IPF treatment I Year: 2016 Final analysis of RECAP, an open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2016 – IPF treatment I Year: 2016 Patterns of discontinuation in the long-term RECAP study of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2017 – Idiopathic pulmonary fibrosis (IPF): treatment highlights Year: 2017 Aspergillus pulmonary disease in cystic fibrosis (CF) patients: multicentre perspective observational study based on new diagnostic tests to evaluate the prognostic value on the CF disease Source: Virtual Congress 2021 – Adult cystic fibrosis Year: 2021 Effect of metformin on clinically relevant outcomes in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2017 – ILDs: clinical aspects Year: 2017 Gait speed and prognosis in patients with idiopathic pulmonary fibrosis: a prospective cohort study Source: Eur Respir J, 53 (2) 1801186; 10.1183/13993003.01186-2018 Year: 2019 Baseline characteristics and survival of patients with idiopathic pulmonary fibrosis (IPF): analysis from the Swedish IPF registry Source: Virtual Congress 2020 – Real life in the field of idiopathic pulmonary fibrosis: treatments and registries Year: 2020 Idiopathic pulmonary fibrosis (IPF) patients in Poland – preliminary cohort analysis of EMPIRE registry Source: International Congress 2017 – ILDs: clinical aspects Year: 2017 Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis Year: 2012 Home oxygen saturation monitoring and quality of life in patients with idiopathic pulmonary fibrosis: A prospective multicenter trial Source: Annual Congress 2013 –Diffuse parenchymal lung disease II Year: 2013 Body composition and mortality in idiopathic pulmonary fibrosis (IPF): a prospective cohort study. Source: International Congress 2018 – Let’s interact and discuss the hot topics in pulmonary rehabilitation Year: 2018 All-case post-marketing surveillance (PMS) of pirfenidone in Japan: Clinical characteristics, efficacy and safety profile in >1300 patients with idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view Year: 2013